Addendum: Nasal NK/T cell lymphoma presents with long-term nasal blockage and fever: a rare case report and literature review
Oncotarget. 2023 Dec 1;14:946. doi: 10.18632/oncotarget.28285.NO ABSTRACTPMID:38039411 | PMC:PMC10691816 | DOI:10.18632/oncotarget.28285 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Hai Zou Ke-Hua Pan Liang Wu Hong-Ying Pan Ya-Hui Ding Ming-Hua Zheng Source Type: research

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
Oncotarget. 2023 Dec 1;14:949-956. doi: 10.18632/oncotarget.28538.ABSTRACTIn myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows good overall response rates in heavily pretreated patients but progression-free survival data are poor. As the drug induces apoptosis, we hypothesized that sBCMA includes extracellular vesicles (EV) and thus evaluated numbers of BCMA-EV before and during belantamab therapy in 10 myeloma patients. BCMA-EV were significantly higher in patients prior to Belantamab (median: 3227/μl; ...
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Carsten Springer J ürgen Krauter Arne Trummer Source Type: research

The double-edge sword of CRISPR application for < em > in vivo < /em > studies
Oncotarget. 2023 Nov 27;14:919-920. doi: 10.18632/oncotarget.28459.NO ABSTRACTPMID:38010820 | PMC:PMC10681099 | DOI:10.18632/oncotarget.28459 (Source: Oncotarget)
Source: Oncotarget - November 27, 2023 Category: Cancer & Oncology Authors: Martin K Thomsen Source Type: research